Loading clinical trials...
Loading clinical trials...
Transvaginal Three-Dimensional Ultrasound in the Evaluation of Intrauterine Device Placement Six Weeks After Insertion: A Cross-Sectional Study
This study aims to evaluate the position of intrauterine devices (IUDs) six weeks after insertion using transvaginal three-dimensional (3D) ultrasound. Women aged 18-45 who undergo postpartum IUD insertion, either vaginally or during cesarean delivery, will be included. The study will compare the accuracy of 3D ultrasound versus conventional two-dimensional (2D) ultrasound in detecting IUD displacement, including partial expulsion, embedment, or perforation. Participants will receive a copper T380A IUD, and all procedures will follow standard clinical protocols. Ultrasound assessments will be conducted six weeks after insertion to confirm proper placement. Data collected will include demographic information, reproductive history, and ultrasound findings. The primary outcome is the prevalence of IUD displacement at six weeks. Secondary outcomes include the diagnostic accuracy of 3D versus 2D ultrasound. This study is designed to improve early detection of malpositioned IUDs, enhancing patient safety and contraceptive effectiveness.
Intrauterine devices (IUDs) are highly effective, long-acting reversible contraceptives. Complications such as expulsion, perforation, and embedment can reduce contraceptive effectiveness and cause abnormal uterine bleeding or pelvic pain. Traditional 2D transvaginal ultrasound may fail to detect malpositioned IUDs, especially levonorgestrel-IUDs or when uterine anomalies are present. 3D transvaginal ultrasound offers improved visualization of the uterine cavity and IUD position. Objectives To evaluate the accuracy of 3D transvaginal ultrasound in detecting IUD displacement six weeks after insertion and compare it to conventional 2D ultrasound. Methods Study Design: Cross-sectional study Setting: Assiut General Hospital and Women's Health Hospital, Assiut, Egypt Duration: July 2025 - June 2026 Participants: Women aged 18-45 receiving postpartum IUD insertion (vaginal or cesarean) Sample Size: 138 women, accounting for 10% loss to follow-up Procedures: Participants provide written informed consent. Baseline data collection: age, parity, residency, educational level, reproductive history, prior IUD use, dysmenorrhea, cervical surgery, lactation status. Copper T380A IUD insertion: Vaginal insertion: sterile technique, uterine sounding, insertion per manufacturer instructions. Cesarean insertion: IUD placed in uterine fundus post-placenta delivery before uterine closure. Follow-up at 6 weeks with 2D and 3D transvaginal ultrasound to assess IUD position. Outcomes: Primary: Prevalence of IUD displacement at 6 weeks Secondary: Accuracy of 3D vs 2D ultrasound in detecting displacement, partial expulsion, embedment, and perforation. Data Management: Data entered and analyzed using SPSS v21. Categorical variables: Chi-square or Fisher's exact test Quantitative variables: Shapiro-Wilkes test for normality; Mann-Whitney or Student's t-test as appropriate Significance: p \< 0.05 Ethical Considerations Study approved by Assiut Faculty of Medicine Ethical Review Committee Conducted according to Declaration of Helsinki and Good Clinical Practice Participant privacy and confidentiality ensured
Age
18 - 45 years
Sex
FEMALE
Healthy Volunteers
Yes
Women's Health Hospital, Assiut
Asyut, Egypt
Start Date
September 1, 2025
Primary Completion Date
August 1, 2026
Completion Date
December 1, 2026
Last Updated
August 22, 2025
138
ESTIMATED participants
2D Transvaginal Ultrasound
BIOLOGICAL
Lead Sponsor
Assiut University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions